High-resolution view of compound promiscuity

Compound promiscuity is defined as the ability of a small molecule to specifically interact with multiple biological targets. So-defined promiscuity is relevant for drug discovery because it provides the molecular basis of polypharmacology, which is increasingly implicated in the therapeutic efficacy of drugs. Recent studies have analyzed different aspects of compound promiscuity on the basis of currently available activity data. In this commentary, we present take-home messages from these studies augmented with new results to generate a detailed picture of compound promiscuity that might serve as a reference for further discussions and research activities.

[1]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[2]  D. Rognan.  Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.

[3]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[4]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[5]  Jürgen Bajorath,et al.  Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families , 2013 .

[6]  J. Bajorath,et al.  What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data , 2013, The AAPS Journal.

[7]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[8]  J. Bajorath,et al.  How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment , 2012, The AAPS Journal.

[9]  J. Bajorath,et al.  Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.

[10]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[11]  J. Mestres,et al.  On the origins of drug polypharmacology , 2013 .

[12]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[13]  Jürgen Bajorath,et al.  Growth of Ligand-Target Interaction Data in ChEMBL Is Associated with Increasing and Activity Measurement-Dependent Compound Promiscuity , 2012, J. Chem. Inf. Model..

[14]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[15]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[16]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.